胶质瘤肿瘤突变负荷的获益证据强度存疑
综述讨论PD-1抑制剂帕博利珠单抗基于TMB-H的泛癌种加速批准在胶质瘤及中枢神经系统肿瘤中的适用性问题。作者指出TMB-H界值未明确定义,胶质瘤具有免疫抑制微环境、全身免疫受影响及T细胞耗竭等内在免疫差异,认为该批准用于CNS肿瘤应谨慎。
要点
- TMB-H界值未明确定义,泛癌种批准证据外推至胶质瘤需谨慎。
- 胶质瘤存在免疫抑制微环境及T细胞耗竭等独特免疫特征。
- 文章呼吁在中枢神经系统肿瘤中谨慎应用该泛癌种批准。
核心结论
- 基于TMB-H的帕博利珠单抗泛癌种批准在胶质瘤及其他CNS肿瘤中的证据可推广性存疑,临床应谨慎应用。
研究设计与样本
- 本文为综述,讨论FDA基于TMB-H对帕博利珠单抗的泛癌种加速批准及胶质瘤相关证据问题。
主要发现
- FDA加速批准帕博利珠单抗用于TMB-H、既往治疗后进展且无其他治疗选择的成人及儿童实体瘤,包括中枢神经系统肿瘤。
- TMB-H的界值未明确定义。
- 胶质瘤与其他癌种存在内在免疫差异,包括免疫抑制性胶质瘤微环境、肿瘤对全身免疫功能的影响及T细胞向耗竭表型转化。
关键数值与推荐
- TMB-H界值未明确定义,原文未给出具体数值。
临床怎么用
- 在胶质瘤及其他CNS肿瘤中应用基于TMB-H的帕博利珠单抗泛癌种批准时应谨慎。
局限性
- 原文未报告具体研究设计、样本量及定量数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The treatment of patients with a variety of solid tumors has benefitted from immune checkpoint inhibition targeting the anti-programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) axis. The US Food and Drug Administration (FDA) granted accelerated approval of PD-1 inhibitor pembrolizumab for the treatment of adult and pediatric patients with TMB-high (TMB-H), solid tumors that have progressed following prior treatment and who have no other treatment options, including the extension to tumors of the Central Nervous System (CNS). In general, pan-cancer approvals are viewed positively to empower patients and clinicians. There are subsets (eg, BRAF, NTRK) for which this pathway for approval is appropriate. However, the pan-cancer FDA approval of pembrolizumab raises several concerns regarding the generalizability of the evidence to other tumor types, including managing patients with gliomas and other CNS tumors. The cut off for TMB-H is not well defined. There are intrinsic immunological differences between gliomas and other cancers types, including the immunosuppressive glioma microenvironment, the tumor's effects on systemic immune function, and the transformation of the T cell populations to an exhausted phenotype in glioma. Here we address the caveats with pan-cancer approvals concerning gliomas, complexities of the unique CNS immune environment, and discuss potential predictive biomarkers, including TMB, and explain why the recent approval should be applied with caution in CNS tumors.
引用
- Khasraw M, Walsh KM, Heimberger AB, et al. What is the Burden of Proof for Tumor Mutational Burden in gliomas? Neuro Oncol. 2020. PMID: 33252666. doi:10.1093/neuonc/noaa256
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。